Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Anastrozole versus progestins/tamoxifen
Thürlimann B. Anastrozole versus progestins/tamoxifen. Eur J Cancer 2002; 38 Suppl 6:S49-51.
01.11.2002Anastrozole versus progestins/tamoxifen
01.11.2002Eur J Cancer 2002; 38 Suppl 6:S49-51
Thürlimann Beat
Mechanism of action of rituximab
Cerny T, Borisch B, Introna M, Johnson P, Rose A. Mechanism of action of rituximab. Anti-cancer drugs 2002; 13 Suppl 2:S3-10.
01.11.2002Mechanism of action of rituximab
01.11.2002Anti-cancer drugs 2002; 13 Suppl 2:S3-10
Cerny Thomas, Borisch Bettina, Introna Martino, Johnson Peter, Rose Andrea L
Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer
Haid A, Kuehn T, Konstantiniuk P, Köberle-Wührer R, Knauer M, Kreienberg R, Zimmermann G. Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur J Surg Oncol 2002; 28:705-10.
01.11.2002Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer
01.11.2002Eur J Surg Oncol 2002; 28:705-10
Haid A, Kuehn T, Konstantiniuk P, Köberle-Wührer R, Knauer Michael, Kreienberg R, Zimmermann G
Gemcitabine-associated hemolytic-uremic syndrome
Walter R, Jörger M, Pestalozzi B. Gemcitabine-associated hemolytic-uremic syndrome. American journal of kidney diseases : the official journal of the National Kidney Foundation 2002; 40:E16.
01.10.2002Gemcitabine-associated hemolytic-uremic syndrome
01.10.2002American journal of kidney diseases : the official journal of the National Kidney Foundation 2002; 40:E16
Walter Roland B, Jörger Markus, Pestalozzi Bernhard C
The war against nicotine and tobacco: new tools?
Cerny T. The war against nicotine and tobacco: new tools?. Onkologie 2002; 25:404.
01.10.2002The war against nicotine and tobacco: new tools?
01.10.2002Onkologie 2002; 25:404
Cerny Thomas
Preclinical development of a vaccine 'against smoking'
Cerny T, Lévy R, Mauel J, Mpandi M, Mutter M, Henzelin-Nkubana C, Patiny L, Tuchscherer G. Preclinical development of a vaccine 'against smoking'. Onkologie 2002; 25:406-11.
01.10.2002Preclinical development of a vaccine 'against smoking'
01.10.2002Onkologie 2002; 25:406-11
Cerny Thomas, Lévy R, Mauel J, Mpandi M, Mutter M, Henzelin-Nkubana C, Patiny L, Tuchscherer G
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
von Rohr A, Tobler A, Betticher D, Cerny T, Fey M, Racine C, Rufener B, Ghielmini M, Zulian G, Konwalinka G, Frickhofen N, Wernli M, Piguet D, Hess U, Tichelli A, Schmitz S, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13:1641-9.
01.10.2002Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
01.10.2002Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13:1641-9
von Rohr A, Tobler A, Betticher D, Cerny Thomas, Fey M F, Racine C, Rufener B, Ghielmini M, Zulian G, Konwalinka G, Frickhofen N, Wernli M, Piguet D, Hess U, Tichelli A, Schmitz S-F H, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells
Scandella E, Men Y, Gillessen Sommer S, Förster R, Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002; 100:1354-61.
15.08.2002Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells
15.08.2002Blood 2002; 100:1354-61
Scandella Elke, Men Ying, Gillessen Sommer Silke, Förster Reinhold, Groettrup Marcus
Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study
Morant R, Hering F, Bauer J, Hanselmann S, Jacky E, Streit A, Forrer P, Egli F, Wernli M, Borner M, Thürlimann B, Bernhard J, Hsu Schmitz S, Schmid H. Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study. European journal of cancer (Oxford, England : 1990) 2002; 38:1626-32.
01.08.2002Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study
01.08.2002European journal of cancer (Oxford, England : 1990) 2002; 38:1626-32
Morant R, Hering F, Bauer J, Hanselmann S, Jacky E, Streit A, Forrer P, Egli F, Wernli M, Borner M, Thürlimann Beat, Bernhard J, Hsu Schmitz S-F, Schmid H-P
Modulation of the endosomal and lysosomal distribution of cathepsins B, L and S in human monocytes/macrophages
Schmid H, Sauerbrei R, Schwarz G, Weber E, Kalbacher H, Driessen C. Modulation of the endosomal and lysosomal distribution of cathepsins B, L and S in human monocytes/macrophages. Biological chemistry 2002; 383:1277-83.
01.07.2002Modulation of the endosomal and lysosomal distribution of cathepsins B, L and S in human monocytes/macrophages
01.07.2002Biological chemistry 2002; 383:1277-83
Schmid Heide, Sauerbrei Ramona, Schwarz Gerold, Weber Ekkehard, Kalbacher Hubert, Driessen Christoph
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Burchert A, Wölfl S, Schmidt M, Brendel C, Denecke B, Cai D, Odyvanova L, Lahaye T, Müller M, Berg T, Gschaidmeier H, Wittig B, Hehlmann R, Hochhaus A, Neubauer A. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2002; 101:259-64.
28.06.2002Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
28.06.2002Blood 2002; 101:259-64
Burchert Andreas, Wölfl Stefan, Schmidt Manuel, Brendel Cornelia, Denecke Barbara, Cai Dali, Odyvanova Larissa, Lahaye Tanja, Müller Martin, Berg Thomas, Gschaidmeier Harald, Wittig Burghardt, Hehlmann Rüdiger, Hochhaus Andreas, Neubauer Andreas
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
Colleoni M, Collins J, Thürlimann B, Holmberg S, Crivellari D, Beyerle C, Neumann R, Goldhirsch A, International Breast Cancer Study Group, Lindtner J, Schmoor C, Rudenstam C, Litman H, Castiglione-Gertsch M, Sauerbrei W, Gelber R, Bonetti M, Coates A, Schumacher M, Bastert G, German Breast Cancer Study Group. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. British journal of cancer 2002; 86:1705-14.
05.06.2002Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
05.06.2002British journal of cancer 2002; 86:1705-14
Colleoni M, Collins J, Thürlimann Beat, Holmberg S B, Crivellari D, Beyerle C, Neumann R L A, Goldhirsch A, International Breast Cancer Study Group, Lindtner J, Schmoor C, Rudenstam C-M, Litman H J, Castiglione-Gertsch M, Sauerbrei W, Gelber R D, Bonetti M, Coates A S, Schumacher M, Bastert G, German Breast Cancer Study Group
Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation
Haid A, Sturn H, Hergan K, Ammann M, Jasarevic Z, Peschina W, Fritzsche H, Burtscher J, Knauer M, Köberle-Wührer R, Zimmermann G. Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation. Breast Cancer Res Treat 2002; 73:31-6.
01.05.2002Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation
01.05.2002Breast Cancer Res Treat 2002; 73:31-6
Haid Anton, Sturn Heinz, Hergan Klaus, Ammann Maria, Jasarevic Zerina, Peschina William, Fritzsche Heinz, Burtscher Judit, Knauer Michael, Köberle-Wührer Roswitha, Zimmermann Gerhard
Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine
Pampallona S, Von Rohr E, Van Wegberg B, Bernhard J, Helwig S, Heusser P, Huerny C, Schaad R, Cerny T. Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine. Onkologie 2002; 25:165-70.
01.04.2002Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine
01.04.2002Onkologie 2002; 25:165-70
Pampallona S, Von Rohr E, Van Wegberg B, Bernhard J, Helwig S, Heusser P, Huerny C, Schaad R, Cerny Thomas
Feasibility and toxicity of weekly Paclitaxel-Carboplatin in 131 patients with pretreated and non-pretreated solid tumors
D'Addario G, Morant R, Boehme C, Cerny T. Feasibility and toxicity of weekly Paclitaxel-Carboplatin in 131 patients with pretreated and non-pretreated solid tumors. Onkologie 2002; 25:152-7.
01.04.2002Feasibility and toxicity of weekly Paclitaxel-Carboplatin in 131 patients with pretreated and non-pretreated solid tumors
01.04.2002Onkologie 2002; 25:152-7
D'Addario G, Morant R, Boehme C, Cerny Thomas
Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo
Scheding S, Bergmann M, Shimosaka A, Wolff P, Driessen C, Rathke G, Jaschonek K, Brugger W, Kanz L. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion 2002; 42:321-7.
01.03.2002Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo
01.03.2002Transfusion 2002; 42:321-7
Scheding Stefan, Bergmann Markus, Shimosaka Akihiro, Wolff Philipp, Driessen Christoph, Rathke Gisa, Jaschonek Karl, Brugger Wolfram, Kanz Lothar
The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer
Huober J, Meyer A, Wagner U, Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. Journal of cancer research and clinical oncology 2002; 128:153-60.
01.03.2002The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer
01.03.2002Journal of cancer research and clinical oncology 2002; 128:153-60
Huober Jens, Meyer A, Wagner U, Wallwiener D
Specific role for cathepsin S in the generation of antigenic peptides in vivo
Plüger E, Boes M, Alfonso C, Schröter C, Kalbacher H, Ploegh H, Driessen C. Specific role for cathepsin S in the generation of antigenic peptides in vivo. European journal of immunology 2002; 32:467-76.
01.02.2002Specific role for cathepsin S in the generation of antigenic peptides in vivo
01.02.2002European journal of immunology 2002; 32:467-76
Plüger Esther B E, Boes Marianne, Alfonso Christopher, Schröter Christian J, Kalbacher Hubert, Ploegh Hidde L, Driessen Christoph
Gemcitabine-related pulmonary toxicity
Jörger M, Gunz A, Speich R, Pestalozzi B. Gemcitabine-related pulmonary toxicity. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2002; 132:17-20.
12.01.2002Gemcitabine-related pulmonary toxicity
12.01.2002Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2002; 132:17-20
Jörger Markus, Gunz A, Speich R, Pestalozzi Bernhard C
Advances in the treatment of non-Hodgkin's lymphoma
Cerny T, Gillessen Sommer S. Advances in the treatment of non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13 Suppl 4:211-6.
01.01.2002Advances in the treatment of non-Hodgkin's lymphoma
01.01.2002Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13 Suppl 4:211-6
Cerny Thomas, Gillessen Sommer Silke